Respiratory Flashcards
COVID-19
Pathogen: SARS-CoV-2 virus
S&S: can occur 2-14 days after exposure
FEver, chills, HA, myalgia, N/V
Can loose taste or smell
Worse if prior respiratory dz
Lung cancer
Screening: Low dose CT if age 55-80 and former smoker
S&S: Cough, hemoptysis, dyspnea, fatigue, weight los, anorexia, fever. Dull, achy chest pain
Signs to look for:
Persistent cough in smoker or former smoker
Recurrent pneumonia (may be tumur in that lung)
Horner syndrome (pupil constriction with ptosis)
NSCLC most common
Carbon monoxide poisoning
S&S: most common, headache
nausea, malaise, and dizziness
Can be like viral URI
Mild confusion to coma
Dx: elevated carboxyhemoglobin level from cooximetry of an arterial blood gas
Pulmonary emboli
Clot in lung
Risk factors: any condition that increases clotting (AF, estrogen, smoking)
S&S: Sudden onset of dyspnea and coughing. Productive of pink-tinged frothy sputum. Tachycardia, pallor, and feelings of impending doom.
Impending respiratory failure (Asthmatic exacerbation)
S&S: tachypnea (>20 breaths/min), tachycardia or bradycardia, cyanosis, and anxiety. uses accessory muscles to help with breathing. “quiet” lungs with no wheezing or breath sounds audible. Trouble talking
Tx: Adrenaline injection stat. Call 911. Oxygen at 4 to 5 L/min; albuterol nebulizer treatments; parenteral steroids, antihistamines (diphenhydramine), and H2 antagonist (cimetidine).
Breath sounds
Lower lobes: Vesicular breath sounds (soft and low)
Upper lobes: Bronchial breath sounds (louder)
Normal respiratory rate
14-18
Small increase in CO2 will increase RR
High levels of CO2 will depress RR
Causes of tachypnea
Increased oxygen demand, hypoxia, and increased PaCO2.
Pain, fear, fever, physical exertion, asthma, pneumonia, PE, and hyperthyroidism.
Egophony
Normal: Will hear “eee” clearly instead of “bah.” The “eee” sound is louder over the large bronchi because larger airways are better at transmitting sounds; lower lobes have a softer-sounding “eee.”
Abnormal: Will hear “bah” sound.
Tactile Fremitus
Instruct patient to say “99” or “one, two, three”; use finger pads to palpate lungs and feel for vibrations going down back
Normal: Stronger vibrations are palpable on the upper lobes and softer vibrations on lower lobes.
Abnormal: The findings are reversed; may palpate stronger vibrations on one lower lobe (i.e., consolidation); asymmetric findings are always abnormal.
Whispered Pectoriloquy
Instruct patient to whisper “one, two, three.” Compare both lungs. If there is lung consolidation, the whispered words are easily heard on the lower lobes of the lungs.
Normal: Voice louder and easy to understand in the upper lobes. Voice sounds are muffled on the lower lobes.
Abnormal: Clear voice sounds in the lower lobes or muffled sounds on the upper lobes.
Percussion
Normal: Resonance is heard over normal lung tissue.
Tympany or hyperresonance: Occurs with chronic obstructive pulmonary disease (COPD), emphysema (overinflating). If empty, the stomach area may be tympanic.
Dull tone: Bacterial pneumonia with lobar consolidation, pleural effusion (fluid or tumor). A solid organ, such as the liver, sounds dull.
Pulmonary Function Testing
Gold standard for asthma and COPD
Forced expiratory volume in 1 second (FEV1): Amount of air that a person can forcefully exhale in 1 second.
Forced vital capacity (FVC): Total amount of air that can be exhaled during the FEV1 test.
FEV1/FVC ratio: Proportion of a person’s vital capacity that the person is able to expire in 1 second. Normal values are ≥75%. Post-bronchodilator FEV1/FVC <0.7 (lung function <70%) is the cutoff score for COPD
COPD Presentation
S&S: Chronic and progressive dyspnea
FEV1/FVC <0.7 - cut off
Typically caused by smoking
Can be mixture of chronic bronchitis & emphysema
Can be asthma–COPD overlap syndrome (ACOS).
Barrel chested - increase AP lateral
Percussion: Hyperresonance
Tactile fremitus and egophony: Decreased
Chest x-ray (CXR): Flattened diaphragms with hyperinflation; bullae sometimes present
Chronic bronchitis
Coughing with excessive mucus production for at least 3 or more months for a minimum of 2 or more consecutive years. May have expiratory wheezing, rhonchi, and coarse crackles.
“blue bloater” - bluish tinge to their skin (due to chronic hypoxia and hypercapnia
Emphysema
Irreversible enlargement and alveolar damage with loss of elastic recoil result in chronic hyperinflation of the lungs. Expiratory respiratory phase is markedly prolonged.
“pink puffer” - pink skin color (adequate oxygen saturation), thin, and tachypneic and uses accessory muscles to breath and pursed-lip breathing.
COPD treatment
GOLD Guidelines
Group A
Minimally symptomatic COPD (low risk of exacerbations)
SABA alone or in combination with SAMA/anticholinergic; combination therapy preferred (more effective) but monotherapy is acceptable
Group B
More symptomatic (low risk of exacerbations)
LAMA or LABA or SABA for symptom relief PRN
Group C
Minimally symptomatic (but high risk of future exacerbations)
LAMA is first line; SABA for symptom relief PRN
Group D
More symptomatic (high risk of future exacerbations)
High risk; refer to pulmonologist
SABAs: Albuterol, levalbuterol (Xopenex), pirbuterol (Maxair)
Long-acting beta-agonists (LABAs): Salmeterol, formoterol, vilanterol
Short-acting anticholinergics or SAMAs: Ipratropium (Atrovent)
Long-acting muscarinic antagonists (LAMAs) or long-acting anticholinergics: Tiotropium bromide (Spiriva), umeclidinium powder (Ellipta), glycopyrrolate (Seebri Neohaler). Available as combination LAMA plus LABA formulations.
primary care for COPD
Smoking cessation
Annual influenza vaccination; give pneumococcal vaccine (PPSV23 [Pneumovax]) and PCV13 [Prevnar]); administer 12 months apart.
Pulmonary hygiene (e.g., postural drainage) or pulmonary rehabilitation
Treat lung infections aggressively.
SABAs are contraindicated for who?
(albuterol, levalbuterol, or metaproterenol)
May cause adverse cardiac side effects (palpitations, tachycardia). Use with caution if patient has hypertension, angina, and/or hyperthyroidism. Avoid combining with caffeinated drinks.
Anticholinergics Contraindications
(ipratropium [Atrovent], tiotropium [Spiriva]):
Avoid if patient has narrow-angle glaucoma, benign prostatic hyperplasia (BPH), or bladder neck obstruction.
COPD exacerbations
Most common cause, respiratory infections
suspect secondary bacterial infection if acute onset of fever, purulent sputum, increased wheezing, and dyspnea.
If increased dyspnea, increased sputum/viscosity, increased sputum purulence) -> hospitalizaion
SABAs are mainstay therapy
First-line treatment for mild COPD (group A)
Either a SABA or a short-acting anticholinergic (or SAMA). If poor relief on single agent, add a second agent. If on SABA, add short-acting anticholinergic (Atrovent).
If short-acting bronchodilators are not controlling symptoms, next step is to start patient on a long-acting bronchodilator (LAMA or LABA) based on patient preference. Continue using SABA as needed
Community-Acquired Pneumonia
The bacteria causing the most deaths in outpatients is S. pneumoniae (gram positive). It is the most common cause of focal infiltrate on a CXR (lobar pneumonia).
S&S: sudden high fever, chills, anorexia, and fatigue. Productive cough with sputum. Sharp stabbing chest pain (pleuritic chest pain) with coughing and dyspnea
Dx: CXR gold standard, repeat within 6 weeks to show clearing
tx: First-line agents (amoxicillin or doxycycline
Alternative macrolide (azithromycin or clarithromycin)
IF comorbidity or high rates of resistance: Combination therapy (beta-lactam plus macrolide or doxycycline): Amoxicillin–clavulanate + Azithromycin
Poor prognosis (refer for hospitalization):
Elderly: Age 60 years or older, acute mental status changes, CHF
Multiple lobar involvement
Acute mental status change
Alcoholics (aspiration pneumonia)
Patient meets the “CURB-65” criterion for hospital admission
C (confusion)
U (blood urea nitrogen >19.6 mg/dL)
R (respiration >30 breaths/min)
B (blood pressure <90/60 mmHg)
Age 65 years or older
Pneumococcal Vaccines
PCV13 (pneumococcal conjugate vaccine: Prevnar 13) recommended for all children <2 years or >2 years with certain medical conditions. Adults aged ≥65 years can use the vaccine (discuss and decide with their clinician). Space at least 1 year apart from PPSV23.
PPSV23 (pneumococcal polysaccharide vaccine: Pneumovax 23, Pnu-Imune 23) recommended. Give first if over 65.
If PPSV23 administered prior to age 65, administer another dose of PPSV23 at least 5 years apart. If after 65, usually good for lifetime.